The March Group

The March Group is a thematic venture capital firm focused on investing in exponential technology platforms that advance human health, planetary health, and the transformation of the global food system. Operating at the intersection of deep technology and impact-driven investing, the firm targets emerging companies building next-generation solutions across life sciences, food technology, and environmental innovation. The March Group's investment thesis centers on what it describes as a "new food paradigm" — backing startups and growth-stage companies that are reimagining how food is produced, distributed, and consumed at scale. This positions the firm within a rapidly evolving landscape of alternative proteins, precision fermentation, regenerative agriculture technology, and related food-tech verticals. As a thematic investor, The March Group concentrates its capital and expertise in convergent areas where biotechnology, computational science, and sustainability-oriented innovation intersect with large, addressable consumer and industrial markets. The firm's dual focus on human and planetary health reflects a conviction that the next wave of transformative companies will address systemic challenges in nutrition, medicine, and ecological systems simultaneously. While specific portfolio companies and fund sizes are not detailed in publicly available content, The March Group positions itself as an early and growth-stage capital partner for founders building platform technologies with the potential for exponential impact. Its thematic approach distinguishes it from generalist venture funds, allowing the firm to develop deep domain expertise and a relevant network within the food-tech and health-tech ecosystems. The firm is relevant to CPG industry stakeholders as a financial backer and strategic partner for emerging ingredient, food technology, and health-oriented brands and platforms seeking venture-scale growth capital.

The Nombase Funding database has 4,288 records from over 1,788 companies.

There's no funding data for this company.